In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biodesix to market VeriStrat companion test for Aveo’s ficlatuzumab

Executive Summary

Biodesix Inc. (multivariate testing in oncology) agreed to market its VeriStrat as a companion diagnostic to cancer company Aveo Pharmaceuticals Inc.’s ficlatuzumab, an anti-hepatocyte growth factor antibody in Phase II for non-small cell lung cancer (NSCLC). VeriStrat is a serum proteomic blood test that stratifies NSCLC patients based on the expected outcome with EGFR tyrosine kinase inhibitor treatment.

Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies